Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
NCT02041234 on ClinicalTrials.gov · last registry update 2022-06-23
Finished December 2020, after enrolling 40 people. Primary outcome, as filed: Number of subjects achieving HBA1c of 6% without diabetic medication.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Khoo Teck Puat Hospital
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2014-02
- Primary completion
- 2020-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of subjects achieving HBA1c of 6% without diabetic medication
Conditions studied
Type II Diabetes in Subjects BMI 27 to 32
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.